Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021051 (immunodeficiency)
 71,517 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A random fragment expression library was used to identify and map a new human epitope on the vpu protein of the human immunodeficiency virus type 1 (HIV-1). The epitope was mapped to the central part of the protein within amino acids (aa) 37-50 comprising the sequence N-KIDRLIDRLI-ERAE-C. A alpha-galactosidase-vpu fusion protein representing aa 37-68 of vpu was used to screen 356 human serum samples from HIV-1-infected persons for antibodies to the novel epitope. A total of 125 (35.1%) of the samples reacted with this region of vpu. Antibodies against this region were significantly more prevalent among samples from individuals with CD4 cell counts < 400 cells/microliters than individuals with CD4 cell counts > or = 400 cells/microliters (37.6 vs. 17.6%; p < 0.0146, Fisher's exact test). Thus, the presence of antibodies against this epitope of vpu appears to be associated with a progressed state of disease.
 ...
PMID:Mapping of a new immunodominant human linear B-cell epitope on the vpu protein of the human immunodeficiency virus type 1. 768 Nov 10

The introduction of molecular therapy through the delivery of nucleic acids either as oligonucleotides or genetic constructs holds enormous promise for the treatment of renal disease. Significant barriers remain, however, before successful organ-specific molecular therapy can be applied to the kidney. These include the development of methods to target the kidney selectively, the definition of vectors that transduce renal tissue, the identification of appropriate molecular targets, the development of constructs that are regulated and expressed for long periods of time, the demonstration of efficacy in vivo, and the demonstration of safety in humans. As the genetic and pathophysiologic basis of renal disease is clarified, obvious targets for therapy will be defined, for example, polycystin in polycystic kidney disease, human immunodeficiency virus (HIV) type 1 in HIV-associated nephropathy, alpha-galactosidase A in Fabry's disease, insulin in diabetic nephropathy, and the "minor" collagen IV chains in Alport's syndrome. In addition, several potential mediators of progressive renal disease may be amenable to molecular therapeutic strategies, such as interleukin-6, basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta(TGF-beta). To test the in vivo efficacy of molecular therapy, appropriate animal models for these disease states must be developed, an area that has received too little attention. For the successful delivery of genetic constructs to the kidney, both viral and nonviral vector systems will be required. The kidney has a major advantage over other solid organs since it is accessible by many routes, including intrarenal artery infusion, retrograde delivery through the uroexcretory pathways, and ex vivo during transplantation. To further restrict expression to the kidney, tropic vectors and tissue-specific promoters also must be developed. For the purpose of inhibition of endogenous or exogenous genes, current therapeutic modalities include the delivery of antisense oligodeoxynucleotides or ribozymes. For these approaches to succeed, we must gain a much better understanding of the nature of their transport into the kidney, requirements for specificity, and in vivo mechanisms of action. The danger of a rush to clinical application is that superficial approaches to these issues will likely fail and enthusiasm will be lost for an area that should be one of the most exciting developments in therapeutics in the next decade.
 ...
PMID:Molecular therapy for renal diseases. 884 Sep 36

Pokeweed antiviral protein (PAP) is a ribosome inactivating protein recognized primarily for its ability to depurinate the sarcin/ricin loop of the large rRNA. Studies have demonstrated that PAP also depurinates other RNA templates, such as Human immunodeficiency virus-1 RNA and Brome mosaic virus RNAs. However, the mechanism by which PAP accesses viral RNAs is not known. Considering that PAP was shown recently to bind the m(7)G of the cap structure, we speculated that PAP may interact with other factors involved in translation initiation. By far western analysis, we show that PAP binds specifically to eIF4G and eIFiso4G of wheat germ and analysis with truncation mutants of eIFiso4G indicates that a region of this protein, between amino acids 511 and 624, is required for PAP binding activity. The yeast two-hybrid system supports these results by showing reduced growth and alpha-galactosidase expression with truncation in this region of eIFiso4G. PAP binds m(7)GTP-Sepharose and this interaction does not diminish the binding of PAP to purified eIFiso4G, indicating that a complex can form among the cap structure, PAP and eIFiso4G. We incubated PAP with uncapped and non-polyadenylated transcripts containing a 3' translation enhancer sequence (TE) known to increase translation of the RNA in an eIF4F dependent manner. We show that in the presence of wheat germ lysate, PAP depurinates the uncapped and non-polyadenylated transcripts containing a functional wild-type 3'TE, but does not depurinate messages containing a non-functional mutant 3'TE. These results support our hypothesis that binding of PAP to eIF4G and eIFiso4G can provide a mechanism for PAP to access both uncapped and capped viral RNAs for depurination.
 ...
PMID:A novel interaction of pokeweed antiviral protein with translation initiation factors 4G and iso4G: a potential indirect mechanism to access viral RNAs. 1649 41

The protein transduction domain from human immunodeficiency virus (HIV) Tat allows proteins to penetrate the cell membrane. Enhanced cellular uptake of therapeutic proteins could benefit a number of disorders. This is especially true for lysosomal storage disorders (LSDs) where enzyme replacement therapy (ERT) and gene therapy have been developed. We developed a novel recombinant lentiviral vector (LV) that engineers expression of alpha-galactosidase A (alpha-gal A)-Tat fusion protein for correction of Fabry disease, the second-most prevalent LSD with manifestations in the brain, kidney and heart. In vitro experiments confirmed mannose-6-phosphate independent uptake of the fusion factor. Next, concentrated therapeutic LV was injected into neonatal Fabry mice. Analysis of tissues at 26 wks demonstrated similar alpha-gal A enzyme activities but enhanced globotriaosylceramide (Gb3) reduction in hearts and kidneys compared with the alpha-gal A LV control. This strategy might advance not only gene therapy for Fabry disease and other LSDs, but also ERT, especially for cardiac Fabry disease.
 ...
PMID:Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice. 2045 22